[go: up one dir, main page]

WO2009144450A1 - Dérivés de tétrahydrofuro[3,2-b]pyrrol-3-one comme inhibiteurs de cystéine protéases - Google Patents

Dérivés de tétrahydrofuro[3,2-b]pyrrol-3-one comme inhibiteurs de cystéine protéases Download PDF

Info

Publication number
WO2009144450A1
WO2009144450A1 PCT/GB2009/001319 GB2009001319W WO2009144450A1 WO 2009144450 A1 WO2009144450 A1 WO 2009144450A1 GB 2009001319 W GB2009001319 W GB 2009001319W WO 2009144450 A1 WO2009144450 A1 WO 2009144450A1
Authority
WO
WIPO (PCT)
Prior art keywords
pyrrol
methyl
oxodihydro
furo
oxoethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2009/001319
Other languages
English (en)
Inventor
Martin Quibell
John Paul Watts
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amura Therapeutics Ltd
Original Assignee
Amura Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amura Therapeutics Ltd filed Critical Amura Therapeutics Ltd
Publication of WO2009144450A1 publication Critical patent/WO2009144450A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Definitions

  • the present invention relates to compounds that are inhibitors of cysteine proteinases, pharmaceutical compositions containing said compounds, and their use in therapy. More specifically, but not exclusively, the invention relates to compounds that are inhibitors of cathepsin K and related cysteine proteinases of the CA clan. Such compounds are particularly useful for the in vivo therapeutic treatment of diseases in which participation of a cysteine proteinase is implicated.
  • Proteinases form a substantial group of biological molecules which to date constitute approximately 2% of all the gene products identified following analysis of several completed genome sequencing programmes. Proteinases have evolved to participate in an enormous range of biological processes, mediating their effect by cleavage of peptide amide bonds within the myriad of proteins found in nature. This hydrolytic action is performed by initially recognising, then binding to, particular three- dimensional electronic surfaces displayed by a protein, which align the bond for cleavage precisely within the proteinase catalytic site. Catalytic hydrolysis then commences through nucleophilic attack of the amide bond to be cleaved either via an amino acid side-chain of the proteinase itself, or through the action of a water molecule that is bound to and activated by the proteinase.
  • cysteine proteinases Proteinases in which the attacking nucleophile is the thiol side-chain of a Cys residue are known as cysteine proteinases.
  • the general classification of 'cysteine proteinase' contains many members found in a wide range of organisms from viruses, bacteria, protozoa, plants and fungi to mammals.
  • Cysteine proteinases are classified into 'clans' based upon a similarity in the three-dimensional structure or a conserved arrangement of catalytic residues within the proteinase primary sequence. Additionally, 'clans' may be further classified into 'families' in which each proteinase shares a statistically significant relationship with other members when comparing the portions of amino acid sequence which constitute the parts responsible for the proteinase activity (see Barrett, A.J et al, in 'Handbook of Proteolytic Enzymes', Eds. Barrett, A. J., Rawlings, N. D., and Woessner, J. F. Publ. Academic Press, 1998, for a thorough discussion).
  • cysteine proteinases have been classified into five clans, CA, CB, CC, CD and CE (Barrett, A. J. et al, 1998).
  • a proteinase from the tropical papaya fruit 'papain' forms the foundation of clan CA, which currently contains over 80 distinct and complete entries in various sequence databases, with many more expected from the current genome sequencing efforts.
  • Proteinases of clan CA / family Cl have been implicated in a multitude of house-keeping roles and disease processes, e.g.
  • human proteinases such as cathepsin K (osteoporosis, osteoarthritis), cathepsin S (multiple sclerosis, rheumatoid arthritis, autoimmune disorders), cathepsin L (metastases), cathepsin B (metastases, arthritis), cathepsin F (antigen processing), cathepsin V (T-cell selection), dipeptidyl peptidase I (granulocyte serine proteinase activation) or parasitic proteinases such as falcipain (malaria parasite Plasmodium falciparum) and cruzipain (Trypanosoma cruzi infection). Recently a bacterial proteinase, staphylopain (S. aureus infection) has also been tentatively assigned to clan CA.
  • X-ray crystallographic structures are available for a range of the above mentioned proteinases in complex with a range of inhibitors e.g. papain (PDB entries, lpad, Ipe6, lpip, lpop, 4pad, 5pad, 6pad, lppp, lthe, lcsb, lhuc), cathepsin K (lauO, Iau2, Iau3, Iau4, latk, lmem, lbgo, layw, layu, Inl6, lnlj, Iq6k, lsnk, Itu6), cathepsin L (Ics8, lmhw), cathepsin S (lglo, Ims6, lnpz), cathepsin V (lfhO), dipeptidyl peptidase I (ljqp, Ik3b), cathepsin B (lgmy, lcsb), cathepsin F (Im6d), cruzain
  • Bone consists of a protein matrix incorporating hydroxyapatite crystals. About 90% of the structural protein of the matrix is type I collagen, with the remainder comprising various non-collagenous proteins such as osteocalcin, proteoglycans, osteopontin, osteonectin, thrombospondin, fibronectin and bone sialoprotein.
  • Skeletal bone is not a static structure but continually undergoes a cycle of bone resorption and replacement. Bone resorption is carried out by osteoclasts, which are multinuclear cells of haematopoietic lineage. Osteoclasts adhere to the bone surface and form a tight sealing zone. The membrane on the apical surface of the osteoclasts is folded so as to create a closed extracellular compartment between the osteoclast and the bone surface, which is acidified by proton pumps in the osteoclast membrane. Proteolytic enzymes are secreted into the compartment from the osteoclast.
  • the high acidity in the compartment causes the hydroxyapatite at the surface of the bone to be dissolved and the proteolytic enzymes break down the protein matrix causing a resorption lacuna to be formed.
  • osteoblasts produce a new protein matrix that is subsequently mineralised.
  • disease states such as osteoporosis and Paget' s disease, the bone resorption and replacement cycle is disrupted leading to a net loss of bone with each cycle. This leads to weakening of the bone and therefore to increased risk of bone fracture.
  • Cathepsin K is expressed at a high level in osteoclasts and is therefore thought to be essential for bone resorption. Thus, selective inhibition of cathepsin K is likely to be effective in the treatment of diseases involving excessive bone loss. These include osteoporosis, gingival diseases such as gingivitis and periodontitis, Paget' s disease, hypercalaemia of malignancy and metabolic bone disease.
  • cathepsin K inhibitors will be of use in the treatment of diseases involving matrix or cartilage degradation, in particular osteoarthritis and rheumatoid arthritis.
  • cysteine proteinase inhibitors for human use has recently been an area of intense activity (e.g. see Deaton, D. N. and Kumar, S., Prog. Med. Chem. 42, 245-375, 2004; Bromme, D. and Kaleta, J., Curr. Pharm. Des., 8, 1639-1658, 2002; Kim, W. and Kang, K., Expert Opin. Ther. Patents, 12(3), 419-432, 2002; Leung-Toung, R. et al. Curr. Med. Chem., 9, 979-1002, 2002; Lecaille, F. et al., Chem. Rev., 102, 4459-4488, 2002; Hernandez, A. A.
  • cathepsin K osteoporosis
  • cathepsin S autoimmune disorders
  • cathepsin L metalastases
  • cathepsin B metalastases, arthritis
  • cathepsin F antigen processing
  • cathepsin V T-cell selection
  • dipeptidyl peptidase I granulocyte serine proteinase activation
  • WO-A-9850533 and WO- A-0029408 describe compounds that may be referred to as cyclic ketones (e.g. l'a-f) and are inhibitors of cysteine proteinases with a particular reference towards papain family proteinases and as a most preferred embodiment, cathepsin K.
  • WO-A-9850533 describes compounds subsequently detailed in the literature as potent inhibitors of cathepsin K with good oral bioavailability (Witherington, J., 'Tetrahydrofurans as Selective Cathepsin K Inhibitors', RSC meeting, Burlington House, London, 1999).
  • WO-A-9850533 The compounds of WO-A-9850533 were reported to bind to cathepsin K through the formation of a reversible covalent bond between the tetrahydrofuran carbonyl and the active site catalytic cysteine residue (Witherington, J., 1999). Additionally, the same cyclic ketone compounds are described in WO-A-9953039 as part of a wide-ranging description of inhibitors of cysteine proteinases associated with parasitic diseases, with particular reference to the treatment of malaria by inhibition of falcipain.
  • the initial cyclic inhibitors of GSK were based upon potent, selective and reversible 3- amido-tetrahydrofuran-4-ones [l'a], 3-amidopyrrolidin-4-ones [l'b], 4-amido- tetrahydropyran-3-ones [l'c], 4-amidopiperidin-3-ones [I'd] and 4-amidoazepan-3-ones [l'e, ITJ (shown above) [see (a) Marquis, R. W. et al, J. Med. Chem. 2001, 44, 725, and references cited therein; (b) Marquis, R. W. et al, J. Med. Chem. 2001, 44, 1380, and references cited therein; (c) Yamashita, D. S. et al, J. Med. Chem. 2006, 49(5), 1597- 1612].
  • the cyclic ketone compounds of WO-A-0069855 are considered to be an advance on compounds of WO-A-9850533 due to the presence of the ⁇ -substituent on the cyclic ketone ring system that provides improved chiral stability to the ⁇ -carbon of the cyclic ketone ring system.
  • the compounds of WO-A-0069855 and indeed those of WO-A-9850533 describe a requirement for the presence of the potential hydrogen- bonding motif X-NHCHRCO-NH-Y that is widely observed amongst the prior art substrate-based inhibitors of CACl proteinases.
  • 5,5-bicyclic inhibitors of CACl cysteinyl proteinases Studies have shown that the above-described 5,5-bicyclic systems exhibit promising potency as inhibitors of a range of therapeutically attractive mammalian and parasitic CACl cysteinyl proteinase targets. Moreover, the 5,5-bicyclic series are chirally stable due to a marked energetic preference for a cw-fused rather than a trans-fased geometry. This chiral stability provides a major advance when compared to monocyclic systems that often show limited potential for preclinical development due to chiral instability.
  • the present inventors have now discovered a small genus of 6-alkyltetrahydrofuro[3,2- ⁇ ]pyrrol-3-ones that exhibit potent in vitro inhibition versus human cathepsin K.
  • a first aspect of the invention relates to a compound of formula (I), or a pharmaceutically acceptable salt, hydrate, complex or pro-drug thereof,
  • R 1 and R 2 are H, and the other is selected from Ci-g-alkyl, C 3-6 -CyClOaIlCyI and C 1-
  • R 3 is selected from tert-butyl, cyclopentyl and 1-methylcyclopentyl
  • R is selected from:
  • Xi, X 2 , X3, X 4 , Xi4, Xi ⁇ X 16 , X 2 o and X 2 i are each independently selected from:
  • CH, C-F, C-Cl and N such that a maximum of two of Xi, X 2 , X3, X 4 , X14, Xi 5 , Xi 6 , X 2 oandX 2 i are chosen as C-F, C-Cl, N or Me;
  • Xi 7 is selected from:
  • X 18 is selected from:
  • X 19 is selected from: CH, CMe, C-F, C-Cl and N;
  • X 22 and X 24 are each independently selected from:
  • X 23 is selected from:
  • X 23 may additionally be ) C-O or S(O) 2 ;
  • X 25 is selected from:
  • X26, X27, X28 and X 29 are each independently selected from:
  • X30 is selected from:
  • X 33 is selected from:
  • X 34 is selected from:
  • R 1 Q is selected from:
  • T 1 , T 2 , T 3 and T 4 are each independantly selected from:
  • CH, CMe, C-F, C-Cl and N such that a maximum of one of Ti, T 2 , T 3 and T 4 is chosen as C-F and C-Cl;
  • T 5 is selected from:
  • T 6 , T 7 , T 8 , T 9 and T 10 are each independantly selected from: CH, CMe, C-F, C-Cl and N: such that a maximum of two of T 6 , T 7 , T 8 , T 9 and T 10 are chosen as C-F, C-Cl and N;
  • T 11 is selected from:
  • T 12 is selected from:
  • T 13 and Ti 4 are each independantly selected from: CH, CMe, C-F and C-Cl;
  • Ti 5 is selected from:
  • Ti 6 is selected from:
  • R 1O is selected from:
  • Ci-6-alkyl OH, Ci- ⁇ -alkoxy, NO 2 , halo, CN, C(O)NH 2 , C(O)NH(C 1-6 - alkyl), C(O)N(C 1-6 -alkyl) 2 , C(O)NH(C 3 - 6 -cycloalkyl), S(O) 2 NH 2 , StOMCi-e-alkyl), S(O) 2 NH(C 1-6 -alkyl), S(O) 2 N(C , ⁇ -alkyl) 2 ,
  • R 11 is selected from C 1-6 -alkyl, C(O)C 1-6 -OIlCyI, C(O)(C 3-6 -cycloalkyl), C(O)(aryl), C(O)NH 2 , C(O)NH(C 1-6 -alkyl), C(O)N(C 1-6 -alkyl) 2 , C(O)NH(C 3-6 -cycloalkyl), C(O)O(Ci.
  • R 12 is selected from H and Ci- 6 -alkylj
  • Ri 3 is selected from:
  • Ti, T 2 , T 3 , T 4 , T 5 , Te, T 7 , T 8 , T 9 , Tio and Ti 3 are as previously defined;
  • R1 3 is selected from:
  • n O or 1 ; and R 14 is selected from H, d- ⁇ -alkyl, C(O)C i-e-alkyl, C(O)(C 3-6 -cycloalkyl),
  • R 15 is selected from H and Ci- ⁇ -alkyl.
  • compounds of formula (I) exhibit surprisingly high efficacies for human cathepsin K.
  • preferred compounds of formula (I) exhibit surprisingly good stability in plasma and microsome assays.
  • a second aspect of the invention relates to a pharmaceutical or veterinary composition
  • a pharmaceutical or veterinary composition comprising a compound of formula (I) and a pharmaceutically acceptable or veterinarily acceptable diluent, excipient and/or carrier.
  • a third aspect of the invention relates to a process for preparing a pharmaceutical or veterinary composition as defined above, said process comprising admixing a compound of the invention with a pharmaceutically acceptable or veterinarily acceptable diluent, excipient and/or carrier.
  • a fourth aspect of the invention relates to compounds of formula (I) for use in medicine.
  • a fifth aspect of the invention relates to the use of a compound of formula (I) in the preparation of a medicament for treating a disease selected from osteoporosis, Paget' s disease, Chagas's disease, malaria, gingival diseases, hypercalaemia, metabolic bone disease, diseases involving matrix or cartilage degradation, and bone cancer disorders such as bone metastases and associated pain.
  • a disease selected from osteoporosis, Paget' s disease, Chagas's disease, malaria, gingival diseases, hypercalaemia, metabolic bone disease, diseases involving matrix or cartilage degradation, and bone cancer disorders such as bone metastases and associated pain.
  • a sixth aspect of the invention relates to a method of inhibiting a cysteine proteinase in a cell, said method comprising contacting said cell with a compound of formula (I).
  • a seventh aspect of the invention relates to method of inhibiting a cysteine proteinase in a subject, said method comprising administering to the subject a pharmacologically effective amount of a compound of formula (I).
  • An eighth aspect of the invention relates to a method of treating a disease selected from osteoporosis, Paget' s disease, Chagas's disease, malaria, gingival diseases, hypercalaemia, metabolic bone disease, diseases involving matrix or cartilage degradation, and bone cancer disorders such as bone metastases and associated pain, in a subject, said method comprising administering to the subject a pharmacologically effective amount of a compound of formula (I).
  • a ninth aspect of the invention relates to the use of a compound according to the invention in an assay for identifying further candidate compounds capable of inhibiting one or more cysteine proteinases.
  • a tenth aspect of the invention relates to the use of a compound of formula (I) in the validation of a known or putative cysteine proteinase as a therapeutic target.
  • An eleventh aspect of the invention relates to a process of preparing a compound of formula (I).
  • alkyl' as applied herein includes stable straight and branched chain aliphatic carbon chains which may be optionally substituted. Preferred examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, t-butyl, pentyl, isopentyl, hexyl, heptyl and any simple isomers thereof. Suitable substituents include, for example, one or more C 1- ealkoxy, OH, COOH, COOMe, NH 2 , NMe 2 , NHMe, NO 2 , CN, CF 3 and/or halo groups.
  • alkyl group contains two or more contiguous carbon atoms
  • the alkyl group may optionally contain one or more heteroatoms for example, to give ethers, thioethers, sulphones, sulphonamides, substituted amines, amidines, guanidines, carboxylic acids, carboxamides. If the heteroatom is located at a chain terminus then it is appropriately substituted with one or two hydrogen atoms.
  • the group CH 3 -CH 2 -O-CH 2 -CH 2 - is defined within 'alkyl' as a C4 alkyl that contains a centrally positioned heteroatom whereas the group CHa-CH 2 -CH 2 -CH 2 - is defined within 'alkyl' as an unsubstituted C4 alkyl.
  • the alkyl group is a C 1-8 alkyl group, more preferably a C 1-6 group, even more preferably a C 1-4 alkyl group.
  • cycloalkyl refers to a cyclic alkyl group (i.e. a carbocyclic ring) which may be substituted (mono- or poly-) or unsubstituted. Suitable substituents include, for example, one or more C 1-6 alkyl, Ci ⁇ alkoxy, OH, COOH, COOMe, NH 2 ,
  • cycloalkyl group is a
  • C 3-8 cycloalkyl group more preferably a C 3-6 -cycloalkyl, even more preferably a C 3 -4 cycloalkyl group.
  • Examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and the like.
  • the carbocyclic ring itself may optionally contain one or more heteroatoms, for example, to give a heterocycloalkyl group such as tetrahydrofuran, pyrrolidine, piperidine, piperazine or morpholine.
  • 'alkyoxy' refers to the group 'O-alkyP or 'O-cycloalkyl', wherein alkyl and cycloalkyl are as defined above.
  • alkyl-aryl' as applied herein includes an alkyl group as defined above in combination with an aryl group.
  • the aryl group may be an aromatic ring, for example, a stable 5 or 6-membered monocylic or a stable 9 or 10-membered bicyclic ring which is unsaturated.
  • the aryl group may optionally comprise one or more heteroatoms selected from O, N and S.
  • the aryl group may be optionally substituted, for example, by one or more C 1-6 alkoxy, OH, COOH, COOMe, NH 2 , NMe 2 , NHMe, NO 2 , CN, CF 3 and/or halo groups.
  • the alkyl-aryl group is a Ct-s-alkyl-Cs-io-aryl group, even more preferably a C 1-8 -alkyl-phenyl group. More preferably still, the alkyl-aryl group is selected from CH 2 Ph and CH 2 OCH 2 Ph. 'Halogen' or 'halo' as applied herein encompasses F, Cl, Br, L
  • Heteroatom' as applied herein encompasses O, S, P and N, more preferably, O, S and N.
  • the present invention includes all salts, hydrates, solvates, complexes and prodrugs of the compounds of this invention.
  • the term "compound” is intended to include all such salts, hydrates, solvates, complexes and prodrugs, unless the context requires otherwise.
  • ketone group of the bicycle core of compounds of formula (I) may exist in alternative forms such as the hydrate (as shown below), and the invention extends to all such alternative forms.
  • the compound of the invention is of formula Ia
  • R 1 , R 2 and R 9 are as defined above, and R 3 is selected from ter t-buty ⁇ , cyclopentyl and 1-methylcyclopentyl;
  • one of R 1 and R 2 is H, and the other is selected from methyl, ethyl, propyl, iso-propyl, ter/-butyl, cyclopropyl, cyclopropylmethyl, iso-propylmethyl, ter/-butylmethyl, CH 2 OH, CH 2 OMe, CH 2 OCH 2 Ph, CH 2 Ph, CH 2 F and CHF 2 .
  • one of R 1 and R 2 is H, and the other is Cj- 8 -alkyl.
  • one of R 1 and R 2 is H, and the other is selected from methyl, ethyl, iso-propyl and CHF 2 .
  • one of R 1 and R 2 is H, and the other is selected as methyl.
  • R 3 is selected from tert-butyl, cyclopentyl and 1- methylcyclopentyl
  • R is cyclopentyl or 1-methylcyclopentyl
  • R 3 is cyclopentyl such that the central moiety is the amino acid (S)-cyclopentylglycine.
  • R is tert-hutyl such that the central moiety is the amino acid ( ⁇ S)-tert-butylglycine.
  • R .3 i •s 1-methylcyclopentyl such that the central moiety is derived from the amino acid ( ⁇ - ⁇ -methylcyclopentylglycine ((S)-2-amino-2- (l-methylcyclopentyl)acetic acid).
  • the compound of the invention is of formula Ib
  • R 1 , R 3 and R 9 are as defined above.
  • R is chosen from:
  • X 2 , X 4 , Xi4, Xi 5 , Xi 6, Xi i, Xi 8, Xi9j X20, X22, X23, X24, X26, X27, X28 and X29 are previously defined and
  • R 13 is chosen from:
  • T 1 , T 2 , T 3 , T 4 , T 5 , T 6 , T 7 , T 8 , T 9 and T 10 are previously defined.
  • R 9 is chosen from:
  • Ri 3 is chosen from:
  • R 9 is chosen from:
  • the compound of the invention is selected from the following: N-((S)-1-cyclopentyl-2-((3aS,6S,6aR)-6-methyl-3-oxodihydro-2H-furo[3,2-b]pyrrol-
  • the compound of the invention is selected from Examples 31-37 and 43-68 described hereinbelow.
  • the compound of the invention is selected from Examples 31, 32, 33, 37, 43-54, 59 and 61 described hereinbelow.
  • a further aspect of the invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of the invention admixed with one or more pharmaceutically acceptable diluents, excipients or carriers.
  • Other active materials may also be present, as may be considered appropriate or advisable for the disease or condition being treated or prevented.
  • the compounds of the present invention can be administered alone, they will generally be administered in admixture with a pharmaceutical carrier, excipient or diluent, particularly for human therapy.
  • a pharmaceutical carrier excipient or diluent
  • the pharmaceutical compositions may be for human or animal usage in human and veterinary medicine.
  • Acceptable carriers or diluents for therapeutic use are well known in the pharmaceutical art, and are described, for example, in Remington's Pharmaceutical Sciences, Mack Publishing Co. (A. R. Gennaro edit. 1985).
  • suitable carriers include lactose, starch, glucose, methyl cellulose, magnesium stearate, mannitol, sorbitol and the like.
  • suitable diluents include ethanol, glycerol and water.
  • compositions may comprise as, or in addition to, the carrier, excipient or diluent any suitable binder(s), lubricant(s), suspending agent(s), coating agent(s), solubilising agent(s).
  • Suitable binders include starch, gelatin, natural sugars such as glucose, anhydrous lactose, free-flow lactose, beta-lactose, corn sweeteners, natural and synthetic gums, such as acacia, tragacanth or sodium alginate, carboxymethyl cellulose and polyethylene glycol.
  • Suitable lubricants include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and the like.
  • Preservatives, stabilizers, dyes and even flavoring agents may be provided in the pharmaceutical composition.
  • preservatives include sodium benzoate, sorbic acid and esters of p-hydroxybenzoic acid.
  • Antioxidants and suspending agents may be also used.
  • a process for the preparation of a pharmaceutical or veterinary composition as described above comprising bringing the active compound(s) into association with the carrier, for example by admixture.
  • the formulations are prepared by uniformly and intimately bringing into association the active agent with liquid carriers or finely divided solid carriers or both, and then if necessary shaping the product.
  • the invention extends to methods for preparing a pharmaceutical composition comprising bringing a compound of general formula (I) in conjunction or association with a pharmaceutically or veterinarily acceptable carrier or vehicle.
  • the compounds of the invention can be present as salts or esters, in particular pharmaceutically and veterinarily acceptable salts or esters.
  • salts of the compounds of the invention include suitable acid addition or base salts thereof.
  • suitable pharmaceutical salts may be found in Berge et al, J Pharm Sci, 66, 1-19 (1977). Salts are formed, for example with strong inorganic acids such as mineral acids, e.g.
  • hydrohalic acids such as hydrochloride, hydrobromide and hydroiodide, sulphuric acid, phosphoric acid sulphate, bisulphate, hemisulphate, thiocyanate, persulphate and sulphonic acids; with strong organic carboxylic acids, such as alkanecarboxylic acids of 1 to 4 carbon atoms which are unsubstituted or substituted (e.g., by halogen), such as acetic acid; with saturated or unsaturated dicarboxylic acids, for example oxalic, malonic, succinic, maleic, fumaric, phthalic or tetraphthalic; with hydroxycarboxylic acids, for example ascorbic, glycolic, lactic, malic, tartaric or citric acid; with aminoacids, for example aspartic or glutamic acid; with benzoic acid; or with organic sulfonic acids, such as or aryl- sulfonic acids which are unsubstituted or substitute
  • Preferred salts include, for example, acetate, trifluoroacetate, lactate, gluconate, citrate, tartrate, maleate, malate, pantothenate, adipate, alginate, aspartate, benzoate, butyrate, digluconate, cyclopentanate, glucoheptanate, glycerophosphate, oxalate, heptanoate, hexanoate, fumarate, nicotinate, pahnoate, pectinate, 3-phenylpropionate, picrate, pivalate, proprionate, tartrate, lactobionate, pivolate, camphorate, undecanoate and succinate, organic sulphonic acids such as methanesulphonate, ethanesulphonate, 2- hydroxyethane sulphonate, camphorsulphonate, 2-naphthalenesulphonate, benzenesulphonate, p-chlorobenzenes
  • Esters are formed either using organic acids or alcohols/hydroxides, depending on the functional group being esterified.
  • Organic acids include carboxylic acids, such as alkanecarboxylic acids of 1 to 12 carbon atoms which are unsubstituted or substituted (e.g., by halogen), such as acetic acid; with saturated or unsaturated dicarboxylic acid, for example oxalic, malonic, succinic, maleic, fumaric, phthalic or tetraphthalic; with hydroxycarboxylic acids, for example ascorbic, glycolic, lactic, malic, tartaric or citric acid; with aminoacids, for example aspartic or glutamic acid; with benzoic acid; or with organic sulfonic acids, such as (C 1 -C 4 )-alkyl- or aryl-sulfonic acids which are unsubstituted or substituted (for example, by a halogen) such as methane- or p-to
  • Suitable hydroxides include inorganic hydroxides, such as sodium hydroxide, potassium hydroxide, calcium hydroxide, aluminium hydroxide.
  • Alcohols include alkanealcohols of 1-12 carbon atoms which may be unsubstituted or substituted, e.g. by a halogen).
  • the invention includes, where appropriate all enantiomers, diastereoisomers and tautomers of the compounds of the invention.
  • the person skilled in the art will recognise compounds that possess optical properties (one or more chiral carbon atoms) or tautomeric characteristics.
  • the corresponding enantiomers and/or tautomers may be isolated/prepared by methods known in the art.
  • Enantiomers are characterised by the absolute configuration of their chiral centres and described by the R- and S-sequencing rules of Cahn, Ingold and Prelog. Such conventions are well known in the art (e.g. see 'Advanced Organic Chemistry', 3 rd edition, ed. March, J., John Wiley and Sons, New York, 1985).
  • Compounds of the invention containing a chiral centre may be used as a racemic mixture, an enantiomerically enriched mixture, or the racemic mixture may be separated using well-known techniques and an individual enantiomer may be used alone.
  • Some of the compounds of the invention may exist as stereoisomers and/or geometric isomers - e.g. they may possess one or more asymmetric and/or geometric centres and so may exist in two or more stereoisomer ⁇ and/or geometric forms.
  • the present invention contemplates the use of all the individual stereoisomers and geometric isomers of those inhibitor agents, and mixtures thereof.
  • the terms used in the claims encompass these forms, provided said forms retain the appropriate functional activity (though not necessarily to the same degree).
  • the present invention also includes all suitable isotopic variations of the agent or a pharmaceutically acceptable salt thereof.
  • An isotopic variation of an agent of the present invention or a pharmaceutically acceptable salt thereof is defined as one in which at least one atom is replaced by an atom having the same atomic number but an atomic mass different from the atomic mass usually found in nature.
  • isotopes that can be incorporated into the agent and pharmaceutically acceptable salts thereof include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulphur, fluorine and chlorine such as 2 H, 3 H, 13 C, 14 C, 15 N, 17 O, 18 0, 31 P, 32 P, 35 S, 18 F and 36 Cl, respectively.
  • isotopic variations of the agent and pharmaceutically acceptable salts thereof are useful in drug and/or substrate tissue distribution studies. Tritiated, i.e., 3 H, and carbon-14, i.e., 14 C, isotopes are particularly preferred for their ease of preparation and detectability. Further, substitution with isotopes such as deuterium, i.e., 2 H, may afford certain therapeutic advantages resulting from greater metabolic stability, for example, increased in vivo half-life or reduced dosage requirements and hence may be preferred in some circumstances.
  • the invention includes compounds of general formula (I) where any hydrogen atom has been replaced by a deuterium atom. Isotopic variations of the agent of the present invention and pharmaceutically acceptable salts thereof of this invention can generally be prepared by conventional procedures using appropriate isotopic variations of suitable reagents.
  • the invention further includes the compounds of the present invention in prodrug form, i.e. covalently bonded compounds which release the active parent drug according to general formula (I) in vivo.
  • prodrugs are generally compounds of the invention wherein one or more appropriate groups have been modified such that the modification may be reversed upon administration to a human or mammalian subject. Reversion is usually performed by an enzyme naturally present in such subject, though it is possible for a second agent to be administered together with such a prodrug in order to perform the reversion in vivo. Examples of such modifications include ester (for example, any of those described above), wherein the reversion may be carried out be an esterase etc. Other such systems will be well known to those skilled in the art.
  • a prodrug may for example constitute a ketal or hemiketal derivative of the exocyclic ketone functionality present in the 6-alkyltetrahydrofuro[3,2-b]pyrrol-3-one scaffold.
  • the present invention also includes solvate forms of the compounds of the present invention.
  • the terms used in the claims encompass these forms.
  • the invention further relates to the compounds of the present invention in their various crystalline forms, polymorphic forms and (an)hydrous forms. It is well established within the pharmaceutical industry that chemical compounds may be isolated in any of such forms by slightly varying the method of purification and or isolation form the solvents used in the synthetic preparation of such compounds.
  • Another aspect of the invention relates to the use of a compound of the invention as defined hereinabove in an assay for identifying further candidate compounds that influence the activity of a cysteine proteinase.
  • the assay is capable of identifying candidate compounds that are capable of inhibiting one or more CACl cysteine proteinases.
  • the assay is a competitive binding assay.
  • the candidate compound is generated by conventional SAR modification of a compound of the invention.
  • conventional SAR modification refers to standard methods known in the art for varying a given compound by way of chemical derivatisation.
  • the identified compound may act as a model (for example, a template) for the development of other compounds.
  • the compounds employed in such a test may be free in solution, affixed to a solid support, borne on a cell surface, or located intracellularly. The abolition of activity or the formation of binding complexes between the compound and the agent being tested may be measured.
  • the assay of the present invention may be a screen, whereby a number of agents are tested.
  • the assay method of the present invention is a high through-put screen.
  • This invention also contemplates the use of competitive drug screening assays in which neutralising antibodies capable of binding a compound specifically compete with a test compound for binding to a compound.
  • HTS high throughput screening
  • the competitive binding assay comprises contacting a compound of the invention with a cysteine proteinase in the presence of a known substrate of said enzyme and detecting any change in the interaction between said cysteine proteinase and said known substrate.
  • a further aspect of the invention provides a method of detecting the binding of a ligand to a cysteine proteinase, said method comprising the steps of:
  • One aspect of the invention relates to a process comprising the steps of: (a) performing an assay method described hereinabove;
  • Another aspect of the invention provides a process comprising the steps of:
  • Another aspect of the invention provides a process comprising the steps of:
  • the invention also relates to a ligand identified by the method described hereinabove.
  • Yet another aspect of the invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising a ligand identified by the method described hereinabove.
  • Another aspect of the invention relates to the use of a ligand identified by the method described hereinabove in the preparation of a pharmaceutical composition for use in the treatment of one or more disorders selected from osteoporosis, Paget' s disease, Chagas's disease, malaria, gingival disease such as gingivitis or periodontitis, hypercalaemia, metabolic bone disease and diseases involving matrix or cartilage degradation, such as osteoarthritis, rheumatoid arthritis and neoplastic diseases.
  • the above methods may be used to screen for a ligand useful as an inhibitor of one or more cysteine proteinases.
  • Compounds of general formula (I) are useful both as laboratory tools and as therapeutic agents. In the laboratory certain compounds of the invention are useful in establishing whether a known or newly discovered cysteine proteinase contributes a critical or at least significant biochemical function during the establishment or progression of a disease state, a process commonly referred to as 'target validation'.
  • a method of validating a known or putative cysteine proteinase as a therapeutic target comprising:
  • the invention therefore provides a method of validating a known or putative cysteine proteinase as a therapeutic target. Differing approaches and levels of complexity are appropriate to the effective inhibition and 'validation' of a particular target, hi the first instance, the method comprises assessing the in vitro binding of a compound of general formula (I) to an isolated known or putative cysteine proteinase, providing a measure of 'potency'. An additional assessment of the binding of a compound of general formula (I) to closely related homologous proteinases of the target and general house-keeping proteinases (e.g. trypsin) provides a measure of 'selectivity'.
  • a compound of general formula (I) to closely related homologous proteinases of the target and general house-keeping proteinases (e.g. trypsin) provides a measure of 'selectivity'.
  • a second level of complexity may be assessed by monitoring a cell-based functional marker of a particular cysteine proteinase activity, in the presence of a compound of general formula (I).
  • a cell-based functional marker of a particular cysteine proteinase activity in the presence of a compound of general formula (I).
  • an Osteoclast resorption assay' has been utilised as a cell- based secondary in vitro testing system for monitoring the activity of cathepsin K and the biochemical effect of proteinase inhibitors (e.g. see WO-A-9850533).
  • An 'MHC-II processing - T-cell activation assay' has been utilised as a cell-based secondary in vitro testing system for monitoring the activity of cathepsin S and the biochemical effect of proteinase inhibitors (Shi, G-P., et al, Immunity, 10, 197-206, 1999).
  • a marker could simply be a functional assessment of viral (e.g. count of mRNA copies) or bacterial loading and assessing the biochemical effect of proteinase inhibitors.
  • a third level of complexity may be assessed by monitoring an animal model-based functional marker of a particular cysteine proteinase activity, in the presence of a compound of general formula (I). For example, murine models of Leishmania infection, P.
  • the invention therefore extends to the use of a compound of general formula (I) in the validation of a known or putative cysteine proteinase as a therapeutic target.
  • BIOLOGICAL ACTIVITY The compounds of the present invention are structurally distinct from the prior art (e.g. WO-A-02057270; Quibell, M. et. al, Bioorg. Med. Chem. 13, 609-625, 2005; Quibell M, et al Bioorg. Med. Chem, 12, 5689-5710, 2004) in that a 6-alkyl substituent is an integral part of the present invention and this provides surprisingly high efficacies for human cathepsin K. Indeed, all of the compounds of the present invention prepared to date exhibit potent in vitro inhibition versus human cathepsin K with Ki ⁇ 20 nM.
  • the majority of the eighty-two prior art compounds detailed in WO-A- 02057270 are significantly less potent against human cathepsin K than the compounds of the present invention and in the majority of examples greater than 1000-fold less potent (for example see table 2).
  • the closest prior art compounds are devoid of a 6- alkyl substituent (e.g. compound 23 (Quibell, M. et. al, Bioorg. Med. Chem. 13, 609- 625, 2005); compound 2 (analogue 21 from WO02057270); compound 1 (an analogue within WO02057270 but not specifically examplifed)) and these exhibit in vitro potency against human cathepsin K of 87, 210 and 5OnM respectively.
  • the compounds exhibit in vitro inhibition versus human cathepsin K with Ki ⁇ 10 nM, more preferably ⁇ 5 nM, even more preferably ⁇ 2 nM and more preferably still ⁇ 1 nM.
  • the compounds of the invention exhibit high selectivity against other mammalian cathepsins displaying little or no inhibitory activity for cathepsins S, L, B and V at 25OnM compound.
  • Compounds of general formula (I) are useful for the in vivo treatment or prevention of diseases in which participation of a cysteine proteinase is implicated.
  • the compound of general formula I is selective for cathepsin K.
  • the term "selective for cathepsin K” means that the inhibitor is selective for cathepsin K over one or more other mammalian CACl cysteinyl proteinases for example cathepsin S, cathepsin L, cathepsin F, cathepsin B and cathepsin V.
  • the inhibitor exhibits a selectivity ratio for cathepsin K over other mammalian CACl cysteinyl proteinases of greater than 2-fold, more preferably greater than 5-fold, more preferably greater than 10-fold, even more preferably greater than 25- fold, more preferably still, greater than 50-fold or 100-fold.
  • a compound of general formula (I) for use in medicine especially for preventing or treating diseases in which the disease pathology may be modified by inhibiting a cysteine proteinase.
  • a compound of general formula (I) in the preparation of a medicament for preventing or treating diseases in which the disease pathology may be modified by inhibiting a cysteine proteinase.
  • cysteine proteinases function in the normal physiological process of protein degradation in animals, including humans, e.g. in the degradation of connective tissue. However, elevated levels of these enzymes in the body can result in pathological conditions leading to disease. Thus, cysteine proteinases have been implicated in various disease states, including but not limited to, infections by Pneumocystis carinii, Trypsanoma cruzi, Trypsanoma brucei brucei and Crithidia fusiculata; as well as in osteoporosis, osteoarthritis, rheumatoid arthritis, multiple sclerosis, chronic pain, autoimmunity, schistosomiasis, malaria, tumour metastasis, metachromatic leukodystrophy, muscular dystrophy, amytrophy, and the like (see WO-A-9404172 and EP-A-0603873 and references cited therein).
  • staphylopain a secreted bacterial cysteine proteinase from S. Aureus called staphylopain has been implicated as a bacterial virulence factor (Potempa, J., et al. J. Biol. Chem, 262(6), 2664-2667, 1998).
  • the invention is useful in the prevention and/or treatment of each of the disease states mentioned or implied above.
  • the present invention also is useful in a method of treatment or prevention of diseases caused by pathological levels of cysteine proteinases, particularly cysteine proteinases of the papain superfamily, which methods comprise administering to an animal, particularly a mammal, most particularly a human, in need thereof a compound of the present invention.
  • the present invention particularly provides methods for treating diseases in which cysteine proteinases are implicated, including infections by Pneumocystis carinii, Trypsanoma cruzi, Trypsanoma brucei, Leishmania mexicana, Clostridium histolyticum, Staphylococcus aureus, foot-and- mouth disease virus and Crithidia fusiculata; as well as in osteoporosis, osteoarthritis, rheumatoid arthritis, multiple sclerosis, chronic pain, autoimmunity, schistosomiasis, malaria, tumour metastasis, metachromatic leukodystrophy, muscular dystrophy, amytrophy.
  • Inhibitors of cathepsin K are useful for the treatment of osteoporosis, Paget' s disease, gingival diseases such as gingivitis and periodontitis, hypercalaemia of malignancy, metabolic bone disease, diseases involving matrix or cartilage degradation, in particular osteoarthritis and rheumatoid arthritis and neoplastic diseases.
  • compositions of the present invention may be adapted for rectal, nasal, intrabronchial, topical (including buccal and sublingual), vaginal or parenteral (including subcutaneous, intramuscular, intravenous, intraarterial and intradermal), intraperitoneal or intrathecal administration.
  • the formulation is an orally administered formulation.
  • the formulations may conveniently be presented in unit dosage form, i.e., in the form of discrete portions containing a unit dose, or a multiple or sub-unit of a unit dose.
  • the formulations may be in the form of tablets and sustained release capsules, and may be prepared by any method well known in the art of pharmacy.
  • Formulations for oral administration in the present invention may be presented as: discrete units such as capsules, gellules, drops, cachets, pills or tablets each containing a predetermined amount of the active agent; as a powder or granules; as a solution, emulsion or a suspension of the active agent in an aqueous liquid or a non-aqueous liquid; or as an oil-in-water liquid emulsion or a water-in-oil liquid emulsion; or as a bolus etc.
  • these compositions contain from 1 to 250 mg and more preferably from 10-100 mg, of active ingredient per dose.
  • the term "acceptable carrier” includes vehicles such as common excipients e.g. binding agents, for example syrup, acacia, gelatin, sorbitol, tragacanth, polyvinylpyrrolidone (Povidone), methylcellulose, ethylcellulose, sodium carboxymethylcellulose, hydroxypropylmethylcellulose, sucrose and starch; fillers and carriers, for example corn starch, gelatin, lactose, sucrose, microcrystalline cellulose, kaolin, mannitol, dicalcium phosphate, sodium chloride and alginic acid; and lubricants such as magnesium stearate, sodium stearate and other metallic stearates, glycerol stearate stearic acid, silicone fluid, talc waxes, oils and colloidal silica.
  • Flavouring agents such as peppermint, oil of wintergreen, cherry flavouring and the like can also be used. It may be desirable to
  • a tablet may be made by compression or moulding, optionally with one or more accessory ingredients.
  • Compressed tablets may be prepared by compressing in a suitable machine the active agent in a free flowing form such as a powder or granules, optionally mixed with a binder, lubricant, inert diluent, preservative, surface-active or dispersing agent.
  • Moulded tablets may be made by moulding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent.
  • the tablets may be optionally be coated or scored and may be formulated so as to provide slow or controlled release of the active agent.
  • compositions suitable for oral administration include lozenges comprising the active agent in a flavoured base, usually sucrose and acacia or tragacanth; pastilles comprising the active agent in an inert base such as gelatin and glycerin, or sucrose and acacia; and mouthwashes comprising the active agent in a suitable liquid carrier.
  • Other forms of administration comprise solutions or emulsions which may be injected intravenously, intraarterially, intrathecally, subcutaneously, intradermally, intraperitoneally or intramuscularly, and which are prepared from sterile or sterilisable solutions. Injectable forms typically contain between 10 - 1000 mg, preferably between 10 - 250 mg, of active ingredient per dose.
  • compositions of the present invention may also be in form of suppositories, pessaries, suspensions, emulsions, lotions, ointments, creams, gels, sprays, solutions or dusting powders.
  • the active ingredient can be incorporated into a cream consisting of an aqueous emulsion of polyethylene glycols or liquid paraffin.
  • the active ingredient can also be incorporated, at a concentration of between 1 and 10% by weight, into an ointment consisting of a white wax or white soft paraffin base together with such stabilisers and preservatives as may be required.
  • DOSAGE A person of ordinary skill in the art can easily determine an appropriate dose of one of the instant compositions to administer to a subject without undue experimentation. Typically, a physician will determine the actual dosage which will be most suitable for an individual patient and it will depend on a variety of factors including the activity of the specific compound employed, the metabolic stability and length of action of that compound, the age, body weight, general health, sex, diet, mode and time of administration, rate of excretion, drug combination, the severity of the particular condition, and the individual undergoing therapy. The dosages disclosed herein are exemplary of the average case. There can of course be individual instances where higher or lower dosage ranges are merited, and such are within the scope of this invention.
  • an effective amount of a compound of general formula (I) may be administered to inhibit the proteinase implicated with a particular condition or disease.
  • this dosage amount will further be modified according to the type of administration of the compound.
  • parenteral administration of a compound of general formula (I) is preferred.
  • An intravenous infusion of the compound in 5% dextrose in water or normal saline, or a similar formulation with suitable excipients, is most effective, although an intramuscular bolus injection is also useful.
  • the parenteral dose will be about 0.01 to about 100 mg/kg; preferably between 0.1 and 20 mg/kg, in a manner to maintain the concentration of drug in the plasma at a concentration effective to inhibit a cysteine proteinase.
  • the compounds may be administered one to four times daily at a level to achieve a total daily dose of about 0.4 to about 400 mg/kg/day.
  • the precise amount of an inventive compound which is therapeutically effective, and the route by which such compound is best administered, is readily determined by one of ordinary skill in the art by comparing the blood level of the agent to the concentration required to have a therapeutic effect.
  • Prodrugs of compounds of the present invention may be prepared by any suitable method. For those compounds in which the prodrug moiety is a ketone functionality, specifically ketals and/or hemiketals, the conversion may be effected in accordance with conventional methods.
  • the compounds of this invention may also be administered orally to the patient, in a manner such that the concentration of drug is sufficient to inhibit bone resorption or to achieve any other therapeutic indication as disclosed herein.
  • a pharmaceutical composition containing the compound is administered at an oral dose of between about 0.1 to about 50 mg/kg in a manner consistent with the condition of the patient.
  • the oral dose would be about 0.5 to about 20 mg/kg.
  • the one or more compounds of the invention are administered in combination with one or more other active agents, for example, existing drugs available on the market.
  • the compounds of the invention may be administered consecutively, simultaneously or sequentially with the one or more other active agents.
  • Drugs in general are more effective when used in combination.
  • combination therapy is desirable in order to avoid an overlap of major toxicities, mechanism of action and resistance mechanism(s).
  • the major advantages of combining chemotherapeutic drugs are that it may promote additive or possible synergistic effects through biochemical interactions and also may decrease the emergence of resistance.
  • Beneficial combinations may be suggested by studying the inhibitory activity of the test compounds with agents known or suspected of being valuable in the treatment of a particular disorder. This procedure can also be used to determine the order of administration of the agents, i.e. before, simultaneously, or after delivery. Such scheduling may be a feature of all the active agents identified herein.
  • One aspect of the invention relates to a process of preparing a compound of formula (I) as defined above, said process comprising oxidation of a compound of formula (II).
  • Any suitable oxidising agent may be used to convert the secondary alcohol group of (II) into the corresponding ketone (I).
  • Suitable oxidising agents will be familiar to the skilled artisan.
  • the oxidation may be carried out via a Dess-Martin periodinane reaction [Dess, D.B. et al, J. Org. Chem. 1983, 48, 4155; Dess, D.B. et al, J.
  • the oxidation can be carried out using SO 3 /pyridine/Et 3 N/DMSO [Parith, J. R. et al, J. Am. Chem. Soc. 1967, 5505; US
  • the process comprises treating a compound of formula (II) with Dess- Martin periodinane.
  • the reaction is carried out using dichloromethane as solvent.
  • R is a protecting group or hydrogen
  • protecting group R 5 is selected from benzyloxycarbonyl, tert-butoxycarbonyl, fluoren-9-ylmethoxycarbonyl, 1 -(biphenyl-4-yl)- 1 - methylethoxycarbonyl, a,a-dimethyl-3,5-dimethoxylbenzyloxycarbonyl, p- methoxybenzyloxycarbonyl, /7-nitrobenzyloxycarbonyl, allyloxycarbonyl and trichloroethoxycarbonyl.
  • R 5 is benzyloxycarbonyl, tert-butoxycarbonyl (Boc) or flouren-9- ylmethoxycarbonyl (Fmoc).
  • R 5 is H.
  • a compound of formula (FVc) may be converted into a compound of formula (1Hb) via the intermediate inverted bromide (FVd)
  • the process of the invention comprises the step of converting a compound of formula (V) into a compound of formula (FV)
  • the intra-molecular cyclisation of compound (V) is induced by removal of the protecting group R 5 .
  • R 5 is benzyloxycarbonyl (Cbz), and the process comprises hydrogenating a compound of formula (V) in the presence of a palladium catalyst.
  • the process of the invention comprises the step of converting a compound of formula (VI) into a compound of formula (V)
  • the oxidising agent is mCPBA.
  • the oxidising agent is a dioxirane.
  • dioxiranes as oxidising agents is well documented in the literature [see (a)
  • the dioxirane is generated in situ by the reaction of KHSO 5 with a ketone.
  • the oxidation step can also be carried out using an isolated dioxirane, for example a stock solution of the dioxirane formed from acetone.
  • the dioxirane is generated in situ using Oxone®, which is a commercially available oxidising agent containing KHSO 5 as the active ingredient.
  • the claimed process involves the in situ epoxidation of a compound of formula (VI) using Oxone® (2KHSOS-KHSO-I-K 2 SO 4 ) and a ketone co-reactant.
  • the active ingredient of Oxone® is potassium peroxymonosulfate, KHSO 5 [CAS-RN 10058-23-8], commonly known as potassium monopersulfate, which is present as a component of a triple salt with the formula 2KHSO 5 -KHSO 4 -K 2 SO 4 [potassium hydrogen peroxymonosulfate sulfate (5:3:2:2), CAS-RN 70693-62-8; commercially available from DuPont].
  • persulfate reacts with the ketone co- reactant to form a three membered cyclic peroxide (a dioxirane) in which both oxygens are bonded to the carbonyl carbon of the ketone.
  • the cyclic peroxide so formed then epoxidises the compound of formula VI by syn specific oxygen transfer to the alkene bond.
  • the ketone is of formula (XIX)
  • R a and R b are each independently alkyl, aryl, haloalkyl or haloaryl.
  • the alkyl group may be a straight chain or branched alkyl group.
  • the alkyl group is a C 1-20 alkyl group, more preferably a C 1-15 , more preferably still a C 1-12 alkyl group, more preferably still, a C 1-8 or C 1 ⁇ alkyl group, more preferably a C 1-4 alkyl group.
  • Particularly preferred alkyl groups include, for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-hutyl, pentyl and hexyl.
  • haloalkyl refers to an alkyl group as described above in which one or more hydrogens are replaced by halo.
  • R a and/or R b are aryl
  • the aryl group is typically a C 6- I 2 aromatic group.
  • Preferred examples include phenyl and naphthyl etc.
  • haloaryl refers to an aryl group as described above in which one or more hydrogens are replaced by halo.
  • R a and R b are as defined above.
  • R a and R b are each independently alkyl or haloalkyl.
  • At least one of R a and R is a haloalkyl, more preferably, CF 3 or CF 2 CF 3 .
  • R a and R b are each independently methyl or trifluoromethyl.
  • the ketone is selected from acetone and a 1,1,1 -trifluoroalkyl ketone.
  • the trifluoroalkyl ketone is 1,1,1- trifluoroacetone or l,l,l-trifluoro-2-butanone, more preferably l,l,l-trifluoro-2- butanone.
  • the process of the invention comprises the step of converting a compound of formula (VII) into a compound of formula (VI)
  • the process comprises treating a compound of formula (VII) with tosyl chloride in pyridine.
  • the process comprises treating a compound of formula (VII) with tosyl chloride in dichloromethane and triethylamine.
  • the process of the invention comprises the step of converting a compound of formula (VIII) into a compound of formula (VII)
  • W is halogen or tosyl
  • this step comprises the steps of:
  • step (b) converting the product formed in step (a) to a compound of formula (VII).
  • steps (a) and (b) of the above process are a one-pot process.
  • R 5 is benzyloxycarbonyl
  • step (b) comprises treating the mixture formed in step (a) with benzyloxycarbonyl chloride.
  • W is I, Br or OTs, more preferably, Br or OTs, even more preferably OTs.
  • the alcohol is isopropyl alcohol or ethanol.
  • said compound of formula VIII is prepared from a compound of formula IX
  • the above process comprises treating said compound of formula IX with methyl lithium. More preferably, compound of formula IX is compound 47 and compound of formula
  • Isosorbide (43) is converted to the di-tosylate (42) which is obtained following recrystallisation from methanol in 97% yield.
  • Mono-bromination is effected by 2.5eq lithium bromide in DMSO (or DMF) with temperature control 110°C-> 12O°C.
  • the product bromide is isolated following extractive work-up and purification either by column chromatography (74%) or attractive for large scale by recrystallisation from methanol giving a first crop of 55% plus mother liquors containing good quality material that may be pooled from batch runs and purified later.
  • preparation of monobromotosylate (47) with defined stereochemistry by methods in Scheme 15 is attractive for large scale applications.
  • Monotosylate can be obtained in higher yield by treatment of isomannide (40) with tosylchloride in pyridine, purification currently requires column chromatography which may becomes undesirable at large scale.
  • Monobromotosylate (46) may then be prepared by treatment of ditosylate (39) with lithium bromide in DMF (29% yield following chromatography) or by treatment of monotosylate under Mitsunobu conditions with carbon tetrabromide (63% yield following chromatography).
  • the 6-alkyl-5,5-bicylic core is prepared in accordance with the steps set forth in Scheme 1 below:
  • the alcohol functionality of (18) may be derivatised as the /? ⁇ r ⁇ -toluene sulphonate (Ts) giving (i?)-2-(benzyloxycarbonylamino)-1-((S)-2,5-dihydrofuran-2-yl)ethyl 4- methylbenzenesulfonate (32b) which proceeds through the ⁇ «t/-epoxide (R)-2- (benzyloxycarbonylamino)-1-((15, 2S, 5S)-3,6-dioxabicyclo[3.1.0]hexan-2-yl)ethyl 4- methylbenzenesulphonate (33b).
  • tosylate (33b) Hydrogenation of tosylate (33b) provides free amine that undergoes intramolecular cyclisation to provide intermediate (74).
  • Intermediate (74) either as the free base or hydrochloride salt, undergoes displacement with an excess of a variety of suitable alkylmetal reagents e.g. a mixture of 2 eq. MeLi to 1 eq.Cu(I)Br that generates Li-Cu(Me) 2 as the active species, to give the 6-alkyl analogues with retention of configuration.
  • the epoxidation to give the desired anfz-epoxide is directed by the presence of the tosylate group.
  • the tosyl group of bicyclic intermediates (74) and (85) can act as a leaving group that undergoes displacement with an excess of a variety of suitable alkylmetal reagents e.g. a mixture of 2 eq. MeLi to 1 eq.Cu(I)Br that generates Li-Cu(Me) 2 as the active species, to give the 6-alkyl analogues with retention of configuration.
  • suitable alkylmetal reagents e.g. a mixture of 2 eq. MeLi to 1 eq.Cu(I)Br that generates Li-Cu(Me) 2 as the active species
  • suitable alkylmetal reagents e.g. a mixture of 2 eq. MeLi to 1 eq.Cu(I)Br that generates Li-Cu(Me) 2 as the active species
  • Isomannide (40) is mono te/t-butyldimethylsilyl (TBDMS) protected by treatment with tert-butyldimethylsilyl chloride and imidazole in DMF to give intermediate (86).
  • tosylate (91a) may be converted to the monobromide (92) by treatment with lithium bromide in DMF.
  • Treatment of bromide (92) with zinc dust in ammonium chloride and THF followed by extraction then treatment with triethylamine and methanesulphonyl chloride provides mesylate (93).
  • Preparation of amine (94) may be achieved by direct treatment of mesylate (93) with ammonia in propan-2-ol or via the 2-step procedure of azide displacement of mesylate with sodium azide in DMF followed by reduction of azide to amine (94) through treatment with triphenylphosphine and water in DMF.
  • Amine (94) may then be Cbz protected by treatment with Cbz-Cl and sodium carbonate in aqueous dioxan.
  • Epoxidation of alkene (95) through use of 1,1,1-trifluoroacetone provides an ⁇ 3.5:1 mixture of the desired anti-(96) and side-product syn-(96) respectively.
  • Treatment of epoxide mixture (96) with sodium hydride in anhydrous THF provides a new slower eluting product on TLC that is the desired bicycle (3R, 3a/f, 6R, 6aR)-benzyl 3- hydroxy-6-methyltetrahydro-2H-furo [3 ,2-b]pyrrole-4(5H)-carboxylate (2a).
  • ketone (87) may be treated with triphenylphosphine and dibromodifluoromethane in N,N-dimethylacetamide to give tert-buty ⁇ ((3R, 3aS, 6aR)- 6-(difluoromethylene)hexahydrofuro [3 ,2-b] furan-3 -yloxy)dimethylsilane (97) as detailed in Scheme 8.
  • novel aminoacid (iS)-2-amino-2-(l-methylcyclopentyl)acetic acid that forms an intrinsic feature of a selection of compounds of formula I may be prepared following adaptation of a variety of known general literature syntheses of aminoacids.
  • commercially available methyl cyclopentanecarboxylate (127) (CAS 4630-80-2) is converted to methyl 2-(l-methylcyclopentyl)acetate (131) as detailed in WO-A-06064286.
  • Ester (131) is readily hydrolysed to 2-(l- methylcyclopentyl)acetic acid (132) using LiOH in methanol.
  • compounds of general formula (I) may be readily synthesised by a number of chemical strategies, performed either in solution or on the solid phase (see Atherton, E. and Sheppard, R. C. In 1 SoHd Phase Peptide Synthesis: A Practical Approach ', Oxford University Press, Oxford, U.K. 1989, for a general review of solid phase synthesis principles), or a combination thereof.
  • Compounds of general formula (I) may be conveniently considered as a combination of three building blocks (Pl, P2 and P3) that respectively occupy the Sl, S2 and S3 binding sites of the protease (see Berger, A and Schechter, L, Philos. Trans. R. Soc. Lond. [Biol], 257, 249-264, 1970 for a description of the designation of enzyme S- subsites and substrate P-subsites within enzyme-substrate or enzyme-inhibitor complexes).
  • Pl, P2 and P3 are used herein for convenience only and the above-mentioned compounds are intended to be within the scope of the invention regardless of binding mode.
  • a suitably protected and/or activated building block may then be prepared and subsequently chemically bonded (coupled) together with other building blocks to provide compounds of general formula (I).
  • Compounds of formula (I) may be prepared: (1) by the stepwise addition of P3 and P2 to the bicyclic 6-alkyltetrahydrofuro[3,2-b]pyrrol-3-one core; or (2) by reaction of the bicyclic 6-alkyltetrahydrofuro[3,2-b]pyrrol-3-one core with a P3-P2 prescursor molecule; or (3) by introducing the P3-P2 group prior to formation of the bicyclic 6- alkyltetrahydrofuro[3,2-b]pyrrol-3-one core, i.e. prior to the oxidation step or prior to the intramolecular cyclisation step.
  • each of the Pl, P2 or P3 building blocks may contain additional alternative functionalities that are further transformed following coupling to give the final compound.
  • the ketone functionality of the Pl building block may be protected as a ketal during coupling of building blocks and transformed to the final ketone by hydrolysis following completion of the coupling reactions.
  • the ketone functionality of the Pl building block may be initially introduced via a lower oxidation state such as the corresponding alcohol and following completion of the coupling reactions be re-introduced by oxidation of the alcohol.
  • the ketone functionality of the Pl building block may be protected through a semi-carbazone suitable for solid phase synthesis (e.g. see WO 02/057270 and references cited therein) and following completion of the coupling reactions released from the solid phase by acidolytic reaction.
  • the chemical bond formed by coupling of the building blocks is a secondary amide (P3-P2) or a tertiary amide (P2-P1) that are formed through reaction of an activated carboxylic acid with a primary and secondary amine respectively.
  • P3-P2 secondary amide
  • P2-P1 tertiary amide
  • Many methods are available for activation of a carboxylic acid prior to coupling to an amine and in principle, any of these methods may be used herein.
  • Typical carboxylic acid activation methods are exemplified but not restricted to the azide method, mixed anhydride method (e.g. via isobutylchloroformate), carbodiimide methods (e.g.
  • dicyclohexylcarbodiimide via dicyclohexylcarbodiimide, diisopropylcarbodiimide, 1 -ethyl-3-(3'-dimethylamino propyl)carbodiimide), active ester method (e.g. via p-nitrophenyl ester, N- hydroxysuccinic imido ester, pentafluorophenyl ester), uronium method (e.g. via addition of HBTU, PyBop, BOP), carbonyldiimidazole method or via pre-formation of acyl fluorides or acyl chlorides.
  • active ester method e.g. via p-nitrophenyl ester, N- hydroxysuccinic imido ester, pentafluorophenyl ester
  • uronium method e.g. via addition of HBTU, PyBop, BOP
  • carbonyldiimidazole method or via
  • the coupling reaction may be enhanced by the addition of a further activation catalyst such as 1- hydroxybenzotriazole, or 4-dimethylaminopyridine.
  • a further activation catalyst such as 1- hydroxybenzotriazole, or 4-dimethylaminopyridine.
  • Bodanszky M. 'Principles of Peptide Synthesis', 2 nd rev. ed., Springer- Verlag, Berlin, 1993 and references cited therein.
  • the ⁇ -amino group of the P2 aminoacid building block is usually protected during coupling reactions to the Pl building block to avoid the formation of undesired self- condensation products.
  • the art of ⁇ -amino protection is well known in peptide chemistry (e.g. see Bodanszky, M. 'Principles of Peptide Synthesis', 2 nd rev.
  • example protection groups include, but are not limited to, 9-fluorenylmethoxycarbonyl (Fmoc), tert- butoxycarbonyl (Boc), benzyloxycarbonyl (Cbz), allyloxycarbonyl (Alloc) and trichloroethoxycarbonyl (Treoc).
  • Fmoc 9-fluorenylmethoxycarbonyl
  • Boc tert- butoxycarbonyl
  • Cbz benzyloxycarbonyl
  • Alloc allyloxycarbonyl
  • Teoc trichloroethoxycarbonyl
  • the Fmoc group is particularly well suited for solid phase syntheses (e.g. see Atherton, E.; Sheppard, R. C.
  • any protecting groups are removed in whatever manner is dictated by the choice of protecting groups (for a general description of protecting groups and their respective stabilities and methods of removal see Greene, T. W. and Wuts, P. G. M. 'Protective Groups in Organic Synthesis' John Wiley and Sons, New York, 1991 and references therein).
  • the entire left hand portion of a compound of general formula (I) i.e. P3-P2 as the carboxylic acid can be prepared in solution by traditional organic chemistry methods and coupled to ketone, alcohol or ketal intermediates such as compounds (lib), (lie) and (Hd). Then oxidation of the alcohol intermediate (e.g. Dess- Martin periodinane in DCM) or acidolytic cleavage of the ketal intermediate provides compounds of general formula (I).
  • the alcohol oxidation route is particularly useful when the compound of general formula (I) contains a substituent that is labile to trifluoroacetic acid, this being the final reagent used in each of the solid phase syntheses.
  • one preferred strategy for the synthesis of compounds of general formula (I) comprises:-
  • a second strategy for the synthesis of compounds of general formula (I) comprises:- (a) Preparation of an appropriately functionalised and protected bicyclic intermediate building block in solution.
  • Preferred protecting groups for solution phase chemistry are the 9-fluorenylmethoxycarbonyl (Fmoc), N ⁇ -tert-butoxycarbonyl (Boc), N ⁇ -benzyloxycarbonyl (Cbz) and N ⁇ -allyloxycarbonyl group (Alloc).
  • compounds of formula (I) may be prepared using conventional solution phase chemistry, for example, as described in Quibell, M et al, Bioorg. Med. Chem, 13, 609-625, 2005 (see in particular, Schemes 3 and 4).
  • the solution phase strategy is attractive in being able to generate larger quantities of preferred analogues, typically on a multi-gram to multi- kilogram scale.
  • compounds of formula (I) may be prepared using conventional solid phase chemistry, for example, as described in Quibell M, et al Bioorg. Med. Chem, 12, 5689-5710, 2004, see in particular, Scheme 3 and Section 3.2, and references cited therein; and Bioorg. Med. Chem, 13, 609-625, 2005, see Scheme 5 and Section 2.2, and references cited therein).
  • the solid phase strategy is attractive in being able to generate many thousands of analogues, typically on a 5-100mg scale, through established parallel synthesis methodologies (e.g. see (a) Bastos, M.; Maeji, N. J.; Abeles, R. H. Proc. Natl. Acad. ScL USA, 92, 6738-6742, 1995).
  • the synthetic strategy is based on reversible anchorage of the ketone functionality via a hydrazide linker bond using general multipin techniques previously described in the art (Watts J. et al, Bioorg. Med. Chem. 12(11), 2903, 2004; Quibell M., et al, Bioorg. Med. Chem. 5689-5710, 2004; Grabowksa U. et al, J. Comb. Chem 2000, 2(5), 475).
  • the semicarbazide 4-[[(hydrazinocarbonyl) amino]methyl]cyclohexane carboxylic acid, trifluoroacetate (Murphy, A. M., et al, J. Am. Chem. Soc, 114, 3156-3157, 1992), may be utilised as illustrated in Scheme 3, exemplified by linkage of the Fmoc protected 6-alkyltetrahydrofuro[3,2-b]pyrrol-3-one (XVI).
  • Construct (XVII) is prepared through reaction of the linker molecule and the 6- alkyltetrahydrofuro[3,2-b]pyrrol-3-one (XVI) by refluxing in aqueous ethanol/sodium acetate. Standard solid phase techniques (e.g. see Atherton, E. and Sheppard, R. C, 1989) are used to anchor the construct to an amino-functionalised solid phase through the free carboxylic acid functionality of (XVII), providing the loaded construct (XVIII). Loaded construct (XVIII) be reacted with a wide range of carboxylic acids available commercially or in the literature, to introduce the left-hand portion 'P3-P2'.
  • HPLC-MS analysis was performed on an Agilent 1100 series LC/MSD, using automated Agilent HPLC systems, with a gradient of 10 to 90% B in A over 10 min on Phenomenex Luna C 8 , 5 ⁇ , 300 A, 50 x 2.0 mm at 0.6 mL / min.
  • Semi- preparative HPLC purification was performed on Phenomenex Jupiter C 4 , 5 ⁇ , 300 A, 250 x 10 mm, using a gradient of 10 to 90% B in A over 25 min at 4 mL / min on automated Agilent systems with 215 and / or 254 nm UV detection. Flash column purification was performed on silica gel 60 (Merck 9385) or using isolute SPE flash silica columns (Biotage, Hengoed, UK).
  • the resulting off-white precipitate comprising a mixture of mono- and bistosylates (approximately 1 : 1), was collected by filtration in vacuo.
  • the filter cake was washed with water then triturated with methanol (500 mL).
  • the solid was isolated by filtration in vacuo to obtain ditosylate (39) as an off-white powder (75 g, 48%).
  • [ ⁇ ] ⁇ 8 +96.7° (c 10.5, CHCl 3 ).
  • the filter cake was washed with diethyl ether (60 mL). Hydrochloric acid (IM, 60 mL) was added to the filtrate then the organic phase separated. The aqueous layer was extracted with diethyl ether (60 mL) then the combined organic phase was washed with brine (60 mL), then dried (MgSO 4 ), filtered and reduced in vacuo. The residue was dissolved in ammonium hydroxide (18 mL) and a solution of ammonia in propan-2-ol (12 mL, 2.0M, 24 mmol) then divided into three equal portions and heated in sealed tubes at 75 °C for 16 hours. The mixtures were combined using methanol then the solvents were removed in vacuo.
  • IM Hydrochloric acid
  • Boc alcohol (35b) (1 LOg, 27.6 mmol) was dissolved in 4N HCl in dioxan (100 mL, 400 mmol) and the mixture stirred at ambient temperature for 1 hour. The mixture was then concentrated in vacuo and azeotroped three times from toluene to give a pale brown solid (Yield 9.25 g).
  • TsOCHCH TsOCHCH
  • 79.15 TsOCHCH
  • 127.84 and 130.40 aromatic CH
  • 132.28 CHOSO 2 C quaternary
  • 145.65 CH 3 C quaternary
  • 1,4-Dioxane 0.7 mL then a solution of sodium carbonate (87 mg, 0.83 mmol) in water (0.6 mL) was added whilst stirring to the crude amine (94) amine (assumed to be 0.33 mmol) followed by benzylchloroformate (0.11 mL, 0.73 mmol). The mixture was stirred for 50 minutes before adding dichloromethane (5 mL) and water (10 mL). The organic phase was separated and the aqueous reextracted with dichloromethane (2 x 5 mL). The combined organic layers were washed with brine (5 mL), then dried (Na 2 SO 4 ), filtered and reduced in vacuo to leave a residue.
  • reaction mixture was diluted with DCM (25 mL), washed with saturated brine (25 mL), dried (Na 2 SO 4 ), filtered and reduced in vacuo to a tan gum (110 mg). Flash chromatography over silica, eluting with ethyl acetate : heptane mixtures 20 : 80 to 50 : 50 gave bicyclic alcohol (108) as a clear gum (53.0 mg, 59.7%).
  • aqueous layer was re-extracted with diethyl ether (150 mL) then the combined organic layers were washed with brine (100 mL), then dried (MgSO 4 ), filtered and the majority of solvents removed in vacuo to leave a yellow oil which was dissolved in dichloromethane (22.5 mL) then cooled to 0 °C.
  • Triethylamine (4.17 mL, 30.0 mmol) then methanesulfonyl chloride (2.32 mL, 30.0 mmol) were added then the suspension stirred for 40 minutes at 0 °C, then at ambient temperature for 35 minutes.
  • Dichloromethane 200 mL was added then the mixture washed with water (75 mL), brine (75 mL), dried (Na 2 SO 4 ), filtered and reduced in vacuo to leave a residue (2.92 g).
  • Tetrabutylammonium fluoride solution (1.0M in tetrahydrofuran, 2.5 mL, 2.5 mmol) was added to a stirred solution of tert-buty ⁇ ((3R, 3aS, 6S, 6aR)-6-(difluoromethyl)hexahydrofuro [3,2-b] furan-3- yloxy)dimethylsilane (98b) (666 mg, 2.26 mmol) in tetrahydrofuran (2.5 mL). The solution was stirred for 45 minutes then dichloromethane (25 mL) was added. The solution was dried (Na 2 SO 4 ), filtered and the majority of solvents removed in vacuo to leave alcohol (99b) which was used without further purification. HPLC-MS 181.0 [M + H] + .
  • 1,4-dioxan (1 mL) over 5 minutes.
  • the mixture was stirred for 1 hour before adding dichloromethane (10 mL) and water (10 mL).
  • the organic phase was separated and the aqueous re-extracted with dichloromethane (10 mL).
  • the combined organic layers were washed with brine (10 mL), then dried (Na 2 SO 4 ), filtered and reduced in vacuo to leave a tan oil (0.6 g).
  • Benzyl chloroformate (0.15 mL, 1.05 mmol) was added then the mixture was stirred for 15 minutes before adding water (30 mL) and dichloromethane (25 mL). The mixture was filtered through celite then the filter cake washed with dichloromethane (15 mL). The organic layer was separated then the aqueous layer extracted with dichloromethane (2 x 10 mL). The combined organic layers were washed with brine (15 mL), dried (Na 2 SO 4 ), filtered and reduced in vacuo to leave a pale brown oil (755 mg).
  • Scheme 14 (a) n-PrMgCl in Et 2 O, Cu(I)Br, LiCl, THF; (b) Cbz-Cl, Na 2 CO 3 , dioxane, H 2 O; (c) Pd-C, H 2 , methanol; (d) Fmoc-Cl, Na 2 CO 3 , dioxane, H 2 O; (e) Dess-Martin periodinane, DCM.
  • the aqueous phase was extracted with dichloromethane (4 x 50 mL), then the combined organic layers were dried (Na 2 SO 4 ), filtered and reduced in vacuo to leave a pale yellow oil.
  • the oil was partitioned between a solution of sodium carbonate (1.4 g) in water (50 mL) and diethyl ether (20 mL).
  • the aqueous layer was re-extracted with diethyl ether (3 x 20 mL) then the pH adjusted to ⁇ 2 using 5M hydrochloric acid.
  • Fmoc-ketone building blocks (2c, 2c', 2d, 2d') may be utilised in a solid phase synthesis of example inhibitors (31-37 and 43-68) of general formula I.
  • the methods used were directly analogous to those described in detail in WO02057270, utilising the 4- ⁇ [(Hydrazinocarbonyl)amino]methyl ⁇ cyclohexane carboxylic acid trifluoroacetate based linker, solid phase lanterns (ex Mimotopes), standard Fmoc chemistries or Boc chemistry with graduated acidolytic deprotection (see WO04007501, pg 309 (iv)) and acidolytic cleavage followed by semi-preparative HPLC purification (see WO02057270 pg 124-127 for full generic details).
  • Alternative EXAMPLES of the invention can readily be prepared by the general methods detailed in WO02057270 through use of the appropriately derivatised R 9 -COOH carboxylic acid and
  • Example 31 N-((S)- 1 -cyclopentyl-2-((3aS',6S,6aR)-6-methyl-3-oxodihydro-2H- furo[3,2-b]pyrrol-4(5H,6H,6aH)-yl)-2-oxoethyl)-4-(5,6-dihydroimidazo[2,l-b] thiazol- 3-yl)benzamide
  • Example 32 N-((S)- 1 -cyclopentyl-2-((3aS,65',6aR)-6-methyl-3-oxodihydro-2H- furo[3,2-b]pyrrol-4(5H,6H,6aH)-yl)-2-oxoethyl)benzo[i/]thiazole-6-carboxamide
  • ⁇ PLC-MS R 1 3.63 min, 411.2 [M + H] + , 429.2 [M + H + 18] + .
  • Example 37 N-((S)- 1 -cyclopentyl-2-((3aS,6S,6aR)-6-methyl-3-oxodihydro-2H- furo [3 ,2-b]pyrrol-4(5H,6H,6aH)-yl)-2-oxoethyl)thieno [2,3 -b]pyridine-2-carboxamide
  • Example 50 N-((S)-2-((3aS,6S,6aR)-6-methyl-3-oxodihydro-2H-furo[3,2-b]pyrrol- 4(5H,6H,6aH)-yl)- 1 -( 1 -methylcyclopentyl)-2-oxoethyl)-2-oxo-2,3 -dihydro- 1 H- benzo[d]imidazole-5-carboxamide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L’invention concerne un composé de formule (I), ou un sel pharmaceutiquement acceptable, un hydrate, un complexe ou un promédicament de celui-ci. Dans ladite formule, R1 ou R2 représente H et l'autre élément est choisi parmi un alkyle en C1-8, un cycloalkyle en C3-6 et un (alkyl en C1-8)(aryle en C5-10); R3 est choisi parmi tert-butyle, cyclopentyle et 1-méthylcyclopentyle; R9 est choisi parmi ce qui suit : (F). L'invention concerne en outre des compositions pharmaceutiques comprenant des composés de formule (I) et l’utilisation de tels composés dans le traitement de diverses maladies.
PCT/GB2009/001319 2008-05-29 2009-05-28 Dérivés de tétrahydrofuro[3,2-b]pyrrol-3-one comme inhibiteurs de cystéine protéases Ceased WO2009144450A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0809776.8 2008-05-29
GBGB0809776.8A GB0809776D0 (en) 2008-05-29 2008-05-29 Compounds

Publications (1)

Publication Number Publication Date
WO2009144450A1 true WO2009144450A1 (fr) 2009-12-03

Family

ID=39637797

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2009/001319 Ceased WO2009144450A1 (fr) 2008-05-29 2009-05-28 Dérivés de tétrahydrofuro[3,2-b]pyrrol-3-one comme inhibiteurs de cystéine protéases

Country Status (2)

Country Link
GB (1) GB0809776D0 (fr)
WO (1) WO2009144450A1 (fr)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2388262A1 (fr) * 2010-05-20 2011-11-23 Stichting Dutch Polymer Institute Nouveaux composants chiraux biosourcés
US9266886B2 (en) 2014-02-03 2016-02-23 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
US9481674B1 (en) 2016-06-10 2016-11-01 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
US9663515B2 (en) 2014-11-05 2017-05-30 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
US9796710B2 (en) 2014-10-14 2017-10-24 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
US9845308B2 (en) 2014-11-05 2017-12-19 Vitae Pharmaceuticals, Inc. Isoindoline inhibitors of ROR-gamma
US10301261B2 (en) 2015-08-05 2019-05-28 Vitae Pharmaceuticals, Llc Substituted indoles as modulators of ROR-gamma
WO2020201572A1 (fr) 2019-04-05 2020-10-08 Université De Bretagne Occidentale Inhibiteurs du récepteur 2 activé par une protéase pour le traitement d'une neuropathie sensorielle induite par une intoxication neurotoxique marine
US10829481B2 (en) 2016-01-29 2020-11-10 Vitae Pharmaceuticals, Llc Benzimidazole derivatives as modulators of ROR-gamma
US10913739B2 (en) 2017-07-24 2021-02-09 Vitae Pharmaceuticals, LLC (121374) Inhibitors of RORγ
US11008340B2 (en) 2015-11-20 2021-05-18 Vitae Pharmaceuticals, Llc Modulators of ROR-gamma
US11186573B2 (en) 2017-07-24 2021-11-30 Vitae Pharmaceuticals, Llc Inhibitors of ROR gamma
KR102638391B1 (ko) * 2023-05-30 2024-02-20 삼화페인트공업주식회사 다이알칸설포닐 아이소소바이드 화합물의 제조 방법, 리튬이차전지용 전해액 첨가제, 리튬이차전지용 전해액 및 리튬이차전지

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008007127A1 (fr) * 2006-07-14 2008-01-17 Amura Therapeutics Limited Dérivés de furo[3,2-b]pyrrol-3-ones et leur utilisation comme inhibiteurs de la cystéinyl protéinase
WO2008007107A1 (fr) * 2006-07-14 2008-01-17 Amura Therapeutics Limited Composés

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008007127A1 (fr) * 2006-07-14 2008-01-17 Amura Therapeutics Limited Dérivés de furo[3,2-b]pyrrol-3-ones et leur utilisation comme inhibiteurs de la cystéinyl protéinase
WO2008007107A1 (fr) * 2006-07-14 2008-01-17 Amura Therapeutics Limited Composés

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2388262A1 (fr) * 2010-05-20 2011-11-23 Stichting Dutch Polymer Institute Nouveaux composants chiraux biosourcés
US10047085B2 (en) 2014-02-03 2018-08-14 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
US9266886B2 (en) 2014-02-03 2016-02-23 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
US11535614B2 (en) 2014-02-03 2022-12-27 Vitae Pharmaceuticals, Llc Dihydropyrrolopyridine inhibitors of ROR-gamma
US9624217B2 (en) 2014-02-03 2017-04-18 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
US10807980B2 (en) 2014-02-03 2020-10-20 Vitae Pharmaceuticals, Llc Dihydropyrrolopyridine inhibitors of ROR-gamma
US10399976B2 (en) 2014-02-03 2019-09-03 Vitae Pharmaceuticals, Llc Dihydropyrrolopyridine inhibitors of ROR-gamma
US9796710B2 (en) 2014-10-14 2017-10-24 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
US10087184B2 (en) 2014-10-14 2018-10-02 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of RORγ
US11001583B2 (en) 2014-11-05 2021-05-11 Vitae Pharmaceuticals, Llc Dihydropyrrolopyridine inhibitors of ROR-gamma
US9845308B2 (en) 2014-11-05 2017-12-19 Vitae Pharmaceuticals, Inc. Isoindoline inhibitors of ROR-gamma
US9663515B2 (en) 2014-11-05 2017-05-30 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
US10301261B2 (en) 2015-08-05 2019-05-28 Vitae Pharmaceuticals, Llc Substituted indoles as modulators of ROR-gamma
US10829448B2 (en) 2015-08-05 2020-11-10 Vitae Pharmaceuticals, Llc Substituted benzoimidazoles as modulators of ROR-γ
US11008340B2 (en) 2015-11-20 2021-05-18 Vitae Pharmaceuticals, Llc Modulators of ROR-gamma
US10829481B2 (en) 2016-01-29 2020-11-10 Vitae Pharmaceuticals, Llc Benzimidazole derivatives as modulators of ROR-gamma
US9481674B1 (en) 2016-06-10 2016-11-01 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
US10913739B2 (en) 2017-07-24 2021-02-09 Vitae Pharmaceuticals, LLC (121374) Inhibitors of RORγ
US11186573B2 (en) 2017-07-24 2021-11-30 Vitae Pharmaceuticals, Llc Inhibitors of ROR gamma
WO2020201572A1 (fr) 2019-04-05 2020-10-08 Université De Bretagne Occidentale Inhibiteurs du récepteur 2 activé par une protéase pour le traitement d'une neuropathie sensorielle induite par une intoxication neurotoxique marine
KR102638391B1 (ko) * 2023-05-30 2024-02-20 삼화페인트공업주식회사 다이알칸설포닐 아이소소바이드 화합물의 제조 방법, 리튬이차전지용 전해액 첨가제, 리튬이차전지용 전해액 및 리튬이차전지

Also Published As

Publication number Publication date
GB0809776D0 (en) 2008-07-09

Similar Documents

Publication Publication Date Title
WO2009144450A1 (fr) Dérivés de tétrahydrofuro[3,2-b]pyrrol-3-one comme inhibiteurs de cystéine protéases
US8877927B2 (en) Furo[3,2-B] pyrrol -3-one derivatives and their use as cysteinyl proteinase inhibitors
US9045492B2 (en) Piperazine compounds
WO2009112839A1 (fr) Composés
US7799791B2 (en) Tetrahydrofuro(3,2-B) pyrrol-3-one derivatives as inhibitors of cysteine proteinases
AU2007274097B2 (en) Tetrahydrofuro [3, 2 -b] pyrrol-3-ones as cathepsin K inhibitors
US8053437B2 (en) Furo[3. 2-B] pyrrol derivatives
US7846935B2 (en) Furo[3,2-B]pyrrol-3-one derivatives and their use as cysteinyl proteinase inhibitors
EP2046798B1 (fr) Dérivés de furo[3,2-b]pyrrol-3-ones et leur utilisation comme inhibiteurs de la cystéinyl protéinase
WO2008007112A1 (fr) Tétrahydrofuro[3,2-b]pyrrol-3-ones et leur utilisation comme inhibiteurs de la cathepsine k

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09754095

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09754095

Country of ref document: EP

Kind code of ref document: A1